UBS Group
NVAX icon

UBS Group’s Novavax NVAX Stock Holding History

UBS Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-170,000
Closed -$816K – 9809
2023
Q4 		$816K Buy
170,000
+120,000
+240% +$735K ﹤0.01% 4671
2023
Q3 		$362K Hold
50,000
– – ﹤0.01% 4908
2023
Q2 		$372K Buy
+50,000
New +$393K ﹤0.01% 5068
2023
Q1 		– Sell
-17,300
Closed -$178K – 10128
2022
Q4 		$178K Sell
17,300
-6,700
-28% -$118K ﹤0.01% 5554
2022
Q3 		$437K Buy
+24,000
New +$1.04M ﹤0.01% 4458
2021
Q2 		– Sell
-100
Closed -$18K – 9667
2021
Q1 		$18K Buy
+100
New +$19.9K ﹤0.01% 7468
2016
Q1 		– Sell
-65
Closed -$11K – 8001
2015
Q4 		$11K Hold
65
– – ﹤0.01% 7232
2015
Q3 		$9K Sell
65
-15
-19% -$3.36K ﹤0.01% 7341
2015
Q2 		$18K Sell
80
-15
-16% -$2.64K ﹤0.01% 6978
2015
Q1 		$16K Sell
95
-1,255
-93% -$204K ﹤0.01% 7216
2014
Q4 		$160K Buy
+1,350
New +$141K ﹤0.01% 5253

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group's NVAX Position: Q1 2026 in Review

UBS Group reduced its Novavax (NVAX) stake by 8.5% in Q1 2026, selling an estimated $3.78M and leaving 4,477,701 shares worth $36.4M. The position accounts for 0.01% of the portfolio, ranked #1961.

UBS Group first reported a position in NVAX in Q4 2014 and has held it in 46 quarters since. The position peaked at $39M in Q4 2024. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • UBS Group held 4,477,701 shares of Novavax worth $36.4M as of Q1 2026.
  • UBS Group sold 416,583 Novavax shares in Q1 2026, an estimated $3.78M.
  • Novavax made up 0.01% of UBS Group's portfolio in Q1 2026, its #1961 holding.
  • UBS Group first reported a position in Novavax in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Novavax position peaked at $39M in Q4 2024.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.